Greenwich Lifesciences Expands European FLAMINGO‑01 Trial & Gains EMA Approval for Combined HLA Groups

Greenwich Lifesciences Expands European Clinical Trial and Secures Regulatory Approval

Greenwich Lifesciences, Inc., a biotechnology company headquartered in Stafford, United States, has announced two significant developments related to its FLAMINGO‑01 clinical trial. The company reported an expansion of trial enrollment across Europe and the receipt of European regulatory approval to combine both human leukocyte antigen (HLA) populations within the study.

Expansion of European Trial Enrollment

According to a statement released on 16 July 2026, Greenwich Lifesciences expanded enrollment in its FLAMINGO‑01 trial to include additional sites throughout Europe. The expansion is intended to accelerate the recruitment of participants and facilitate the collection of data required for the assessment of the trial’s efficacy and safety endpoints. The company emphasized that the broadened enrollment will allow a more comprehensive evaluation of the investigational therapy across diverse patient populations.

European Approval for Combined HLA Populations

On the same day, Greenwich Lifesciences received regulatory approval in Europe to conduct FLAMINGO‑01 using both HLA‑A02:01 and HLA‑A24:02 donor populations. This approval, granted by the European Medicines Agency (EMA), represents a pivotal milestone for the company’s development program. By enabling the combination of these two HLA groups, the company anticipates a more efficient recruitment process and enhanced statistical power for the trial’s primary outcomes.

Strategic Implications

The simultaneous expansion of trial enrollment and the regulatory clearance to combine HLA populations are expected to strengthen Greenwich Lifesciences’ position in the oncology therapeutic landscape. The company’s focus on developing treatments for cancer, particularly within the Texas market, aligns with its broader mission to deliver innovative solutions to patients. The developments are likely to positively influence investor perception, especially considering the company’s recent market performance, with a close price of $19.01 on 15 July 2026 and a market capitalization of approximately $286.8 million.

The company’s website, www.greenwichlifesciences.com , provides further details on its research pipeline and corporate updates.